MRNA
MRNA clinical trials: Moderna, Inc.
Every trial on ClinicalTrials.gov where Moderna, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 148
- Trials linked
- 119
- As lead sponsor
- 29
- As collaborator
- 7
- Primary completions as lead sponsor, next 90 days
MRNA on the catalyst calendar · MRNA registry changes
- Primary completion Dec 7, 2026Sponsor estimatePhase 4NCT07884175A Study of Updated mRNA Seasonal Influenza VaccinesModernaTX, Inc. · Seasonal InfluenzaRecruitingMRNALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 30, 2029Sponsor estimatePhase 2NCT07808697A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1283 in Participants ≥6 Months to <12 Years of AgeModernaTX, Inc. · SARS-CoV-2RecruitingMRNALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 7, 2027Sponsor estimatePhase 1NCT07870330A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy ChildrenModernaTX, Inc. · Seasonal InfluenzaRecruitingMRNALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 14, 2026ActualPhase 1NCT05831111A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy ParticipantsModernaTX, Inc. · Epstein-Barr Virus InfectionCompletedMRNALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 11, 2026Sponsor estimatePhase 4NCT07863635A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing FormulationsModernaTX, Inc. · SARS-CoV-2RecruitingMRNALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 14, 2028Sponsor estimatePhase 1NCT07919210A Study to Investigate the Safety, Reactogenicity, and Immunogenicity of a Preventative Vaccine for Marburg Virus (mRNA-1519) in Healthy...ModernaTX, Inc. · Marburg Virus Disease (MVD)Not yet recruitingMRNALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 1, 2028Sponsor estimatePhase 1NCT07919197A Study to Investigate the Safety and Immunogenicity of mRNA-1469 in African Participants 1 to 65 Years of AgeModernaTX, Inc. · Ebola-Bundibugyo Virus Disease (Ebola-BDBV)Not yet recruitingMRNALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 7, 2026ActualPhase 1/Phase 2NCT05992935Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis...ModernaTX, Inc. · Norovirus Acute GastroenteritisCompletedMRNALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 3, 2027Sponsor estimatePhase 1NCT06880549A Study of mRNA-4106 or mRNA-4200 Administered Alone or in Combination With Anti-Cancer Agents in Participants With Solid TumorsModernaTX, Inc. · Advanced Solid TumorsRecruitingMRNALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 16, 2027Sponsor estimatePhase 4NCT07266558A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk...ModernaTX, Inc. · SARS-CoV-2Active, not recruitingMRNALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 30, 2027Sponsor estimatePhase 1NCT07737717A Study to Investigate the Safety, Reactogenicity, and Immunogenicity of mRNA-1469 Vaccine to Prevent Ebola-Bundibugyo Virus Disease in...ModernaTX, Inc. · Ebola-Bundibugyo Virus Disease (Ebola-BDBV)Active, not recruitingMRNALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 17, 2030Sponsor estimatePhase 1/Phase 2NCT07116616A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple MyelomaModernaTX, Inc. · Relapsed or Refractory Multiple MyelomaRecruitingMRNALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 25, 2025ActualPhase 2NCT06508320A Clinical Study to Investigate the Safety and Immunogenicity in Relation to Product Attributes of mRNA-1083 (Severe Acute Respiratory...ModernaTX, Inc. · InfluenzaCompletedMRNALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 16, 2026Sponsor estimatePhase 1NCT06655870A Study to Investigate Safety and Tolerability of mRNA-0184 Administered Subcutaneously in Healthy ParticipantsModernaTX, Inc. · Healthy ParticipantsRecruitingMRNALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 28, 2025ActualPhase 2/Phase 3NCT05127434A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥60 Years of AgeModernaTX, Inc. · Respiratory Syncytial VirusCompletedMRNALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 21, 2032Sponsor estimatePhase 2NCT03897881An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk...ModernaTX, Inc. · MelanomaActive, not recruitingMRNALeadMRKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 21, 2027Sponsor estimatePhase 1NCT03313778Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid TumorsModernaTX, Inc. · Solid TumorsActive, not recruitingMRNALeadMRKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 21, 2025ActualPhase 3NCT06602024A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of AgeModernaTX, Inc. · Seasonal InfluenzaCompletedMRNALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 20, 2027Sponsor estimatePhase 1NCT07764237A Study to Investigate Safety, Reactogenicity, and Immunogenicity of mRNA-1365 (Profile 2) in Older Healthy AdultsModernaTX, Inc. · Respiratory Syncytial Virus (RSV)RecruitingMRNALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 24, 2026ActualPhase 3NCT06067230A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk AdultsModernaTX, Inc. · Respiratory Syncytial VirusCompletedMRNALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 28, 2027Sponsor estimatePhase 3NCT07496450A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy AdultsModernaTX, Inc. · InfluenzaActive, not recruitingMRNALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 6, 2027Sponsor estimatePhase 2NCT05683457A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Allogenic Hematopoietic Cell...ModernaTX, Inc. · Cytomegalovirus InfectionActive, not recruitingMRNALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2025ActualPhase 1NCT05701800A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ≥50 Years of AgeModernaTX, Inc. · Herpes ZosterTerminatedMRNALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 9, 2028Sponsor estimatePhase 2NCT07561294A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1982 to Prevent Lyme Disease in Healthy Participants (18 to...ModernaTX, Inc. · Lyme DiseaseActive, not recruitingMRNALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 27, 2025ActualPhase 2NCT06097299A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of...ModernaTX, Inc. · Respiratory Syncytial VirusCompletedMRNALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 25 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerShowing the first 25 trials. There are 123 more in this window; the full list is part of TrialScanner.
Unlock with TrialScanner